

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : A61K 31/095, 38/09, 39/44, C07C 69/06, 211/00, 211/06, 233/19, 233/22, 317/14, 323/22, 323/33, C07D 207/00, 233/54, 285/10, 307/64, 315/00, 333/34, 333/36, C08F 6 /00, 8 /00, 8 /40, 112/08, C09K 3 /00, C12N 1 /00, C12P 19 /34, C12Q 1 /00, G01N 33 /53</p>	A1	<p>(11) International Publication Number: WO 95/24186</p> <p>(43) International Publication Date: 14 September 1995 (14.09.95)</p>
<p>(21) International Application Number: PCT/US95/03223</p> <p>(22) International Filing Date: 10 March 1995 (10.03.95)</p> <p>(30) Priority Data: 08/212,024 11 March 1994 (11.03.94) US</p> <p>(60) Parent Application or Grant (63) Related by Continuation US 08/212,024 (CON) Filed on 11 March 1994 (11.03.94)</p> <p>(71) Applicant (for all designated States except US): PHARMA- COPEIA, INC. [US/US]; 201 College Road East, Princeton Forrestal Center, Princeton, NJ 08540 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): BALDWIN, John, J. [US/US]; 621 Gypsy Hill Circle, Gwynedd Valley, PA 19437 (US). OHLMEYER, Michael, H., J. [GB/US]; 9-03</p>	<p>Deer Creek Drive, Plainsboro, NJ 08536 (US). HENDER- SON, Ian [GB/US]; 1302 Deer Creek Drive, Plainsboro, NJ 08536 (US).</p> <p>(74) Agents: LOPEZ, Gabriel et al.; Pharmacoepia, Inc., 201 College Road East, Princeton Forrestal Center, Princeton, NJ 08540 (US).</p> <p>(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published With international search report.</p>	
<p>(54) Title: SULFONAMIDE DERIVATIVES AND THEIR USE</p> <p>(57) Abstract</p> <p>Combinatorial libraries are disclosed which are represented by the formula (I): (T'-L)_n-[Ⓢ]-C(O)-L'-II' wherein: [Ⓢ] is a solid support; T'-L- is an identifier residue; and -L'-II' is a ligand/linker residue. These libraries contain aryl sulfonamides, N-acyl derivatives, and N-substituted pyrrolidines and piperidines of the formula: Y-A-CO-R¹ which are inhibitors of serine proteases and carbonic anhydrase isozymes. They are useful in the treatment of hyper-coagulation disease and ocular diseases such as glaucoma.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

TITLE OF THE INVENTION

SULFONAMIDE DERIVATIVES AND THEIR USE

BACKGROUND OF THE INVENTION

5 There is interest in methods for the synthesis of large
numbers of diverse compounds which can be screened for various
possible physiological or other activities. Techniques have been
developed in which one adds individual units sequentially as part of the
chemical synthesis to produce all or a substantial number of the possible
10 compounds which can result from all the different choices possible at
each sequential stage of the synthesis. For these techniques to be
successful, it is necessary for the compounds to be amenable to methods
by which one can determine the structure of the compounds so made.
Brenner and Lerner (*PNAS USA* 81: 5381-83 (1992)) and WO
93/20242, for example, describe a synthesis wherein oligonucleotides
15 are produced in parallel with and are chemically linked as genetic tags
to oligopeptides as the compounds of interest. WO 93/06121 teaches
methods for particles-based synthesis of random oligomers wherein
identification tags on the particles are used to facilitate identification of
the oligomer sequence synthesized. A detachable tagging system is
20 described in Ohlmeyer *et al.*, *Proc. Natl. Acad. Sci. USA*, 90, 10922-
10926, Dec. 1993.

SUMMARY OF THE INVENTION

25 The present invention relates to combinatorial chemical
libraries of compounds encoded with tags and to the use of these
libraries in assays to discover biologically active compounds. The
present invention also relates to libraries containing aryl sulfonamides,
N-acyl derivatives, and N-substituted pyrrolidines and piperidines and
using these libraries to identify biologically active members by
screening for inhibition of serine proteases such as thrombin and Factor
30 X_a; metallo proteases such as angiotensin converting enzyme (ACE);
and carbonic anhydrase isozymes. The present invention also relates to
members of the library which are inhibitors of carbonic anhydrase and

thrombin. The invention also relates to methods for their preparation, intermediates, and to methods and pharmaceutical formulations for using these aryl sulfonamides, N-acyl derivatives, and N-substituted pyrrolidines and piperidines in the treatment of mammals, especially humans.

Because of their activity as inhibitors of serine proteases and carbonic anhydrase isozymes, the compounds of the present invention are useful in the treatment of hypercoagulation disease, post-myocardial infarction treatment, post-angioplasty treatment, and ocular diseases such as glaucoma.

DETAILED DESCRIPTION OF THE INVENTION

The combinatorial libraries of the present invention are represented by Formula I:




wherein:

\textcircled{S} is a solid support;
 T'-L- is an identifier residue;
 -L'-II' is a ligand/linker residue; and
 q is 3-30.


Preferred compounds of Formula I are those wherein:

T'-L- is of the Formula:




wherein $n = 3-12$ when Ar is pentachlorophenyl and
 $n = 4-6$ when Ar is 2,4,6-trichlorophenyl;

q is 3-13; and
 -L'- is



wherein the left-hand bond as shown is the point of attachment to the solid support and the right hand bond is the point of attachment to the ligand, and B is O or NH, with the proviso that in (b) B is NH when attached to a carbonyl group in the ligand.

Depending on the choice of L' (see Table 1), the ligands of Formula II may be detached by photolytic, oxidative, or other cleavage techniques. For example, when -L'- is (a) and B is O, photolytic detachment may be represented by:




wherein L'' is the residue from L' and II'BH is II.

Therefore, compounds of the present invention are also represented by Formula II




wherein:

R¹ is -N(R⁶)-(CH₂)₂₋₅-Z-(CH₂)₂₋₅-R⁹, -NH(CH₂)₂₋₅-R⁹,





R² is the residue on the α carbon of methionine, O-t-butyl-serine, serine, S-trityl-cysteine, cysteine, aspartic acid-β-t-butyl ester, aspartic acid, glutamic acid-γ-t-butyl ester,

- glutamic acid, N^{ϵ} -trityl-histidine, histidine, N^{ϵ} -Boc-lysine, lysine, N^{γ} -Mtr-arginine, arginine, N^{β} -trityl-asparagine, asparagine, N^{γ} -trityl-glutamine, glutamine, N^{ϵ} -Boc-tryptophan, tryptophan, isoleucine, phenylalanine, glycine, alanine, valine, or leucine;
- 5 R^3 is lower alkyl or $-(CH_2)_m-Q-X$;
- R^4 is $-Q(R^7, R^8)-SO_2NH_2$, $-(CH_2)_m-R^{10}$, with the proviso that when $m = 0$, R^{10} is not OH, lower alkyl, a 6-membered aromatic heterocyclic ring containing 1 or 2 N atoms, heteroaryl-lower alkyl,
- 10






- R^5 is lower alkyl, lower cycloalkyl, alkenyl, alkynyl, a mono- or bicyclic 6- to 10-membered aromatic ring system, or a mono- or bicyclic 5- to 10-membered heteroaromatic ring system containing 1 or 2 N atoms, either system unsubstituted or substituted with 1-2 substituents selected from halogen, alkoxy, alkyl, CF_3 , CN, $-N(\text{lower alkyl})_2$, and acylamino;
- 15
- 20 R^6 is H or lower alkyl;
- R^7, R^8 is each independently H, halogen, lower alkyl, alkoxy, CN, $-NO_2$, $-CO$ -lower alkyl, $-N(\text{lower alkyl})_2$, or $NH-CO$ -lower alkyl;
- R^9 is OH, $CONH_2$, or $COOH$;
- 25 R^{10} is alkoxy, OH, or $COOH$;
- m is 0-6;

- A is $-\text{NH}-\text{CHR}^2-$, $-\text{NH}(\text{CH}_2)_{2-12}-$, , , or the descarboxy residue of a primary or secondary amino acid;
- Q is a 5- or 6-membered aromatic or heteroaromatic ring containing 0-3 heteroatoms selected from O, N, and S, or a bicyclic 9- or 10-membered aromatic or heteroaromatic ring system containing 0-3 heteroatoms selected from O, N, and S;
- X is H, lower alkyl, halogen, alkoxy, CF_3 , CN, $-\text{NO}_2$, $-\text{CO}$ -lower alkyl, $-\text{N}(\text{lower alkyl})_2$, $\text{NH}-\text{CO}$ -lower alkyl, or COOH ;
- Y is $-\text{SO}_2\text{R}^3$, $-\text{COR}^4$, $-\text{CO}-\text{CH}(\text{R}^2)-\text{NHSO}_2\text{R}^3$, $-\text{CO}-\text{CH}(\text{R}^2)-\text{NHCOR}^4$, $-\text{CO}-\text{NHR}^5$, or $-\text{COOR}^5$; and
- Z is $-\text{O}-$, $-\text{S}-$, or $-\text{N}(\text{lower alkyl})-$;
- or a pharmaceutically acceptable salt thereof.


A preferred embodiment of the invention is a compound of Formula II wherein:

Y is




A is $-\text{NH}-\text{CHR}^2-$, $-\text{NH}(\text{CH}_2)_{2-12}-$, , ,
or the decarboxy residue of a primary or secondary amino acid; and

R^1 is



Another preferred embodiment of the invention is a compound of Formula II wherein:

Y is



10 One embodiment of the invention is the use of the combinatorial library of Formula I in assays to discover biologically active compounds (ligands) of Formula II. Thus, an aspect of the invention is a method of identifying a compound having a desired characteristic which comprises synthesizing a combinatorial library of
15 Formula I and testing the compounds of Formula I and the ligands of Formula II, either attached to the solid support or detached therefrom, in an assay which identifies compounds having the desired characteristic. A further embodiment of the invention is determining the structure of any compound so identified.

20 Another embodiment of the invention is an improved process for preparing t-butyl 4-(hydroxymethyl)-3-nitrobenzoate from t-butyl 4-(acetoxymethyl)-3-nitrobenzoate which comprises hydrazinolysis of the acetoxymethyl-nitrobenzoate using hydrazine or hydrazine hydrates in polar solvents such as lower alkanols, e.g.

methanol and isopropanol, and aprotic polar solvents such as acetonitrile at 0-50 °C. The improved process produces the hydroxymethyl-nitrobenzoate in nearly quantitative yield. When 4-(acetoxymethyl)-3-nitrobenzoic acid is linked to the solid support., the improved process
5 for removing the alcohol protecting group, i.e., with hydrazine and methanol, is highly superior to the prior art methods.

Another embodiment of the invention is the use of divinylbenzene-cross-linked, polyethyleneglycol-grafted polystyrene beads optionally functionalized with amino groups (for example,
10 TentaGel® S NH₂, Rapp Polymere) as the solid supports for constructing combinatorial libraries. Use of these beads greatly enhances the yield of ligands, e.g., compounds of Formula II, detached from the solid supports. Yields of ligands from supports such as DVB-crosslinked polystyrene are relatively low (<10%). The use of DVB-
15 crosslinked, PEG-grafted polystyrene produces yields of >60%.

Definitions

The following abbreviations have the indicated meaning:

	c-	=	cyclo
	DEAD	=	diethylazodicarboxylate
20	DCM	=	dichloromethane = methylene chloride
	DIC	=	diisopropylcarbodiimide
	DMAP	=	4-N,N-dimethylaminopyridine
	DMF	=	N,N-dimethylformamide
	DVB	=	1,4-divinylbenzene
25	EDT	=	ethane dithiol
	FACS	=	fluorescence activated cell sorting
	Fmoc	=	9-fluorenylmethoxycarbonyl

	GC	=	gas chromatography
	HOBt	=	N-hydroxybenzotriazole
	im	=	imidazole
	in	=	indole
5	m-	=	meta
	Me	=	methyl
	Mtr	=	4-methoxy-2,3,6-trimethylbenzenesulfonyl
	PEG	=	polyethylene glycol
	Ph	=	phenyl
10	r.t.	=	room temperature
	sat'd	=	saturated
	s-	=	secondary
	t-	=	tertiary
	TFA	=	trifluoroacetic acid
15	THF	=	tetrahydrofuran

Alkyl is intended to include linear, branched, or cyclic structures and combinations thereof. "Lower alkyl" includes alkyl groups of from 1 to 8 carbon atoms. Examples of lower alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, s- and t-butyl, pentyl, hexyl, octyl, and the like. "Lower cycloalkyl" includes cycloalkyl groups of from 3 to 8 carbon atoms. Examples of lower cycloalkyl groups include c-propyl, c-butyl, c-pentyl, 2-methylcyclopropyl, cyclopropylmethyl, adamantly, and the like.

"Alkenyl" is C₃-C₆ alkenyl of a linear, branched, or cyclic (C₅-C₆) configuration and combinations thereof. Examples of alkenyl

groups include allyl, isopropenyl, pentenyl, hexenyl, c-hexenyl, 1-propenyl, 2-butenyl, 2-methyl-2-butenyl, and the like.

"Alkynyl" is C₃-C₆ alkynyl of a linear or branched configuration and combinations thereof. Examples of alkenyl groups include propyne, butyne, pentyne, 3-methyl-1-butyne, 3,3-dimethyl-1-butyne, and the like.

"Alkoxy" means alkoxy groups of from 1 to 6 carbon atoms of a straight, branched, or cyclic configuration. Examples of alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, cyclohexyloxy, and the like.

"Acylamino" means acylamino groups of from 1 to 6 carbon atoms of a straight, branched or cyclic configuration. Examples of acylamino groups are acetylamino, butylamino, cyclohexylamino, and the like.

Halogen includes F, Cl, Br, and I.

R² is intended to include racemates and all optical isomers. The amino acid residues of R² are, for example, methyl (alanine), hydroxymethyl (serine), phenylmethyl (phenylalanine), thiomethyl (cysteine), carboxyethyl (glutamic acid), etc.

In R⁴, "heteroaryl" means an aromatic 5- to 10-membered mono- or bicyclic heterocyclic ring system containing 1 or 2 N atoms, the systems either unsubstituted or substituted with 1-2 substituents selected from halogen, alkoxy, alkyl, CF₃, CN, -N(lower alkyl)₂, and acylamino;

In R⁵, the aromatic 6- to 10-membered carbocyclic rings include benzene and naphthalene and the 5- to 10-membered aromatic heterocyclic rings include imidazole, pyridine, and indole.

In A, the primary or secondary amino acids are intended to include alanine, asparagine, aspartic acid, arginine, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, sarcosine, L-alanine, chloro-L-alanine hydrochloride, 2-aminoisobutyric acid, 2-(methylamino)isobutyric acid, DL-3-aminoisobutyric acid, DL-2-aminoisobutyric acid, (R)-(-)-2-aminoisobutyric acid, (S)-(+)-2-aminoisobutyric acid, D-t-leucine, L-t-leucine, D-norvaline, L-norvaline, L-2-amino-4-pentenoic acid, D-

- isoleucine, L-isoleucine, D-norleucine, 2,3-diaminopropionic acid monohydrochloride, L-norleucine, DL-2-aminocaprylic acid, β -alanine, DL-3-aminobutyric acid, 4-aminobutyric acid, 4-(methylamino)butyric acid hydrochloride, 5-aminovaleric acid, 7-aminoheptanoic acid, 8-aminocaprylic acid, 11-aminodecanoic acid, 12-aminododecanoic acid, carboxymethoxylamine hemihydrate, D-serine, D-homoserine, L-homoserine, L-(+)-canavaninesulfate homohydrate, D-allothreonine, L-allothreonine, D-threonine, L-threonine, DL-4-amino-3-hydroxybutyric acid, DL-3-hydroxynorvaline, (3S,4S)-(-)-statine, 5-hydroxy-DL-lysine hydrochloride, 5-aminoleucinic acid hydrochloride, 1-amino-1-cyclopropanecarboxylic acid, 1-amino-1-cyclopentanecarboxylic acid, 1-amino-1-cyclohexanecarboxylic acid, 5-amino-1,3-cyclohexadiene-1-carboxylic acid hydrochloride, 2-amino-2-norbornanecarboxylic acid, (S)-(-)-2-azetidinecarboxylic acid, cis-4-hydroxy-D-proline, cis-4-hydroxy-L-proline, trans-4-hydroxy-L-proline, 3,4-dehydro-DL-proline, 3,4-dehydro-L-proline, D-pipecolinic acid, L-pipecolinic acid, mimosine, 2,3-diaminopropionic acid monohydrobromide, DL-2,4-diaminobutyric acid dihydrochloride, (S)-(+)-diaminobutyric acid hydrochloride, D-ornithine hydrochloride, L-ornithine hydrochloride, 2-methylornithine hydrochloride monohydrate, N- ϵ -methyl-L-lysine hydrochloride, N-methyl-D-aspartic acid monohydrate, DL--2-methylglutamic acid hemihydrate, DL-2-aminoadipic acid, D-2-aminoadipic acid, L-2-aminoadipic acid, (+/-)-3-aminoadipic acid, D-cysteine hydrochloride monohydrate, D-penicillamine, L-penicillamine, DL-homocysteine, S-methyl-L-cysteine, L-methionine, D-ethionine, L-ethionine, S-carboxymethyl-L-cysteine, (S)-(+)-2-phenylglycine, (R)-(-)-2-phenylglycine, N-phenylglycine, N-(4-hydroxyphenyl)glycine, D-phenylalanine, (S)-(-)-indoline-2-carboxylic acid, α -methyl,DL-phenylalanine, β -methyl-DL-phenylalanine hydrochloride, D-homophenylalanine, L-homophenylalanine, DL-2-fluorophenylglycine, DL-2-fluorophenylalanine, DL-3-fluorophenylalanine, DL-4-fluorophenylalanine, DL-4-chlorophenylalanine, L-4-chlorophenylalanine, 4-bromo-DL-phenylalanine, 4-iodo-D-phenylalanine, 3,3',5-triiodo-L-thyronine, (+)-3,3',5-triiodo-L-thyronine sodium salt, D-thyronine, L-thyronine,

DL-m-tyrosine, D-4-hydroxyphenylglycine, D-tyrosine, L-tyrosine, o-methyl-L-tyrosine, 3-fluoro-DL-tyrosine, 3-iodo-L-tyrosine, 3-nitro-L-tyrosine, 3,5-diiodo-L-tyrosine dihydrate, DL-dopa, L-dopa, 2,4,5-trihydroxyphenyl-DL-alanine, 3-amino-L-tyrosine
5 dihydrochloride monohydrate, 4-amino-D-phenylalanine hydrate, 4-amino-L-phenylalanine hydrate, 4-amino-DL-phenylalanine hydrate, 4-nitro-L-phenylalanine monohydrate, 4-nitro-DL-phenylalanine, 3,5-dinitro-L-tyrosine monohydrate, DL- α -methyltyrosine, L- α -methyltyrosine, (-)-3-(3,4-dihydroxyphenyl)-2-methyl-L-alanine
10 sesquihydrate, DL-threo-3-phenylserine hydrate, and DL-DOPS.

Q is intended to include phenyl, thienyl, furanyl, thiadiazolyl, pyridyl, and pyrimidyl.

L and L' are depicted in Table 1, which also shows cleavage reagents. In designing a synthetic scheme, L and L' are chosen
15 such that they are orthogonally reactive, i.e., they must allow for removal of either T or II (where T = T'-OH) without removal of the other since simultaneous cleavage of both T and II from the solid support is disadvantageous. In the structures as shown, the left-hand bond is the point of attachment to the solid support and the right-hand
20 bond is the point of attachment to either T or II.

The tags of this invention, T, are chemical entities which possess several properties: they must be detachable from the solid supports, preferably by photolysis or oxidation; they must be individually differentiable, and preferably separable; they must be
25 stable under the synthetic conditions; they must be capable of being detected at very low concentrations, e.g., 10^{-18} to 10^{-9} mole; they should be identifiable with readily-available equipment which does not require sophisticated technical capabilities to operate; and they should be relatively economical. The tags may be structurally related or
30 unrelated, e.g., a homologous series, repetitive functional groups, related members of the Periodic Chart, different isotopes, combinations thereof, and the like. At the end of the combinatorial synthesis, to each solid support, there will usually be attached at least 0.01 femtomol, usually 0.001-50 pmol, of each tag. The tags may be aliphatic, alicyclic, aromatic, heterocyclic, or combinations thereof. Distinguishing
35 features may be the number of repetitive units, such as methylene

groups in an alkyl moiety; alkyleneoxy groups in a polyalkyleneoxy moiety; halo groups in a polyhalo compound; α - and/or β -substituted ethylene groups where the substituents may be alkyl groups, oxy, carboxy, amino, halo, or the like; isotopes; etc.










5 The materials upon which the combinatorial syntheses of the invention are performed are referred to as solid supports, beads, and resins. These terms are intended to include:

 a) beads, pellets, disks, fibers, gels, or particles such as cellulose beads, pore-glass beads, silica gels, polystyrene beads
10 optionally cross-linked with divinylbenzene and optionally grafted with polyethylene glycol and optionally functionalized with amino, hydroxy, carboxy, or halo groups, grafted co-poly beads, poly-acrylamide beads, latex beads, dimethylacrylamide beads optionally cross-linked with
15 N,N'-bis-acryloyl ethylene diamine, glass particles coated with hydrophobic polymer, etc., i.e., material having a rigid or semi-rigid surface; and

 b) soluble supports such as low molecular weight non-cross-linked polystyrene.

 It is intended that the definitions of any substituent or
20 symbol (e.g., R^2 , R^8 , m, etc.) in a particular molecule be independent of its definitions elsewhere in the molecule.

TABLE 1
LINKER GROUPS

	Linker Group	Cleavage Reagent
5	1.  or 	$h\nu$
10	2. 	$h\nu$
	3. 	$\text{Ce}(\text{NH}_4)_2(\text{NO}_3)_6$
15	4. 	$\text{Ce}(\text{NH}_4)_2(\text{NO}_3)_6$
	5. $-\text{CH}=\text{CH}(\text{CH}_2)_2-$	O_3 , $\text{OsO}_4/\text{IO}_4^-$, or KMnO_4
	6. $-\text{CH}=\text{CHCH}_2-$	O_3 , $\text{OsO}_4/\text{IO}_4^-$, or KMnO_4
	7. $-\text{CH}_2\text{CH}=\text{CH}-$	O_3 , $\text{OsO}_4/\text{IO}_4^-$, or KMnO_4
20	8. 	1) O_2 or Br_2 , MeOH 2) H_3O^+
	9. $-\text{CH}=\text{CHCH}_2\text{O}-$	$(\text{Ph}_3\text{P})_3\text{RhCl}(\text{H})$
	10. 	Li , Mg , or BuLi
25	11. $-\text{S}-\text{CH}_2-\text{O}-$	Hg^{+2}
	12. 	Zn or Mg
	13. 	Oxidation, e.g., $\text{Pb}(\text{OAc})_4$ or H_5IO_6

30 R = H or lower alkyl

X = electron withdrawing group such as Br, Cl, and I.

Optical Isomers - Diastereomers - Geometric Isomers

Some of the compounds described herein contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisometric forms which may be defined in terms of absolute stereochemistry as (R) or (S), or as (D) or (L) for amino acids. The present invention is meant to comprehend all such possible diastereomers as well as their racemic and optically pure forms. Optically active (R) and (S), or (D and L), isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. When the compounds described herein contain olefinic double bonds, and unless specified otherwise, it is intended to include both E and Z geometric isomers.

Salts

The pharmaceutical compositions of the present invention comprise a compound of Formula II as an active ingredient or a pharmaceutically acceptable salt thereof, and may also contain a pharmaceutically acceptable carrier and, optionally, other therapeutic ingredients. The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic acids or bases including organic and inorganic acids or bases.

When a compound of the present invention is acidic, salts may be prepared from pharmaceutically acceptable non-toxic bases. Salts derived from all stable forms of inorganic bases include aluminum, ammonium, calcium, copper, iron, lithium, magnesium, manganese, potassium, sodium, zinc, etc. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion-exchange resins such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, isopropylamine, lysine, methylglucosamine,

morpholine, piperazine, piperidine, polyamine resins, procaine, purine, theobromine, triethylamine, trimethylamine, tripropylamine, etc.

When a compound of the present invention is basic, salts may be prepared from pharmaceutically acceptable non-toxic acids.

- 5 Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic, etc. Particularly preferred are citric,
10 hydrobromic, maleic, phosphoric, sulfuric, and tartaric acids.

In the discussion of methods of treatment herein, reference to the compounds of Formula II is meant to also include the pharmaceutically acceptable salts thereof.

Utilities

- 15 The ability of the compounds of Formula II to inhibit serine proteases makes them useful for preventing or reversing the symptoms induced by these enzymes in a mammal. This enzyme inhibition indicates that the compounds are useful to treat, prevent, or ameliorate hyper-coagulation disease in mammals, especially in humans,
20 and are useful in post-myocardial infarction treatment and in post-angioplasty treatment.

- The ability of compounds to inhibit metallo proteases such as angiotensin converting enzyme makes them useful for preventing or reversing the symptoms induced by these enzymes in a mammal. This
25 enzyme inhibition indicates that the compounds are useful to treat, prevent, or ameliorate hypertension in mammals, especially in humans.

- The ability of the compounds of Formula II to inhibit carbonic anhydrase isozymes makes them useful for preventing or reversing the symptoms induced by these enzymes in a mammal. This
30 enzyme inhibition indicates that the compounds are useful to treat, prevent, or ameliorate ocular diseases, particularly glaucoma in mammals, especially in humans.

Dose Ranges

The magnitude of the prophylactic or therapeutic dose of the compounds of Formula II will vary with the nature and severity of the condition to be treated and with the particular compound of Formula II and its route of administration. In general, the daily dose range for anti-enzymic use lies in the range of 20 to 0.001 mg/kg body weight of a mammal, preferably 10 to 0.01 mg/kg, and most preferably 1.0 to 0.1 mg/kg, in single or divided doses. In some cases, it may be necessary to use doses outside these ranges.

When a composition for intravenous administration is employed, a suitable daily dosage range is from about 10 to 0.0005 mg (preferably 5 to 0.01 mg) compound of Formula II per kg body weight.

When a composition for oral administration is employed, a suitable daily dosage range is from about 20 to 0.001 mg (preferably 10 to 0.01 mg) compound of Formula II per kg body weight.

When a composition for ophthalmic administration is employed, a suitable daily dosage range is from about 10-0.01% (preferably 5.0-0.5% compound of Formula II, typically prepared as a 2.0-0.1% by weight solution or suspension of a compound of Formula II in an acceptable ophthalmic formulation.

The compounds of Formula II may also be used in combination with other pharmaceutically active ingredients. For example, a typical ocular formulation may comprise the compound alone or in combination with a β -adrenergic blocking agent such as timolol maleate or a parasympathomimetic agent such as pilocarpine. When used in combination, the two active ingredients are present in approximately equal parts.

Pharmaceutical Compositions

Any suitable route of administration may be employed for providing a mammal, especially a human, with an effective dosage of a compound of Formula II. For example, oral, rectal, topical, parenteral, ocular, pulmonary, nasal, etc. routes may be employed. Dosage forms

include tablets, troches, dispersions, suspensions, solutions, capsules, creams, ointments, aerosols, and the like.

5 The pharmaceutical compositions of the present invention comprise a compound of Formula II, or a pharmaceutically acceptable salt thereof, as an active ingredient, and may also contain a pharmaceutically acceptable carrier and, optionally, other therapeutically active ingredients.

10 The compositions include compositions suitable for oral, rectal, topical (including transdermal devices, aerosols, creams, ointments, lotions, and dusting powders), parenteral (including subcutaneous, intramuscular, and intravenous), ocular (ophthalmic), pulmonary (nasal or buccal inhalation), or nasal administration; although the most suitable route in any given case will depend largely on the nature and severity of the condition being treated and on the
15 nature of the active ingredient. They may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.

20 A compound of Formula II may be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending on the nature of the preparation desired for administration, i.e., oral, parenteral, etc. In preparing oral dosage forms, any of the usual pharmaceutical media may be used, such as water, glycols, oils, alcohols, flavoring agents,
25 preservatives, coloring agents, and the like in the case of oral liquid preparations (e.g., suspensions, elixirs, and solutions); or carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, etc. in the case of oral solid preparations such as powders, capsules, and tablets. Solid oral
30 preparations are preferred over liquid oral preparations. Because of their ease of administration, tablets and capsules are the preferred oral dosage unit form. If desired, capsules may be coated by standard aqueous or non-aqueous techniques.

In addition to the dosage forms described above, the compounds of Formula II may be administered by controlled release means and devices such as those described in U.S.P. Nos. 3,536,809; 3,598,123; 3,630,200; 3,845,770; 3,916,899; and 4,008,719, which
5 are incorporated herein by reference.

Pharmaceutical compositions of the present invention suitable for oral administration may be prepared as discrete units such as capsules, cachets, or tablets each containing a predetermined amount of the active ingredient in powder or granular form or as a solution or
10 suspension in an aqueous or nonaqueous liquid or in an oil-in-water or water-in-oil emulsion. Such compositions may be prepared by any of the methods known in the art of pharmacy. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers, finely divided solid carriers, or both and
15 then, if necessary, shaping the product into the desired form. For example, a tablet may be prepared by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as powder or granule optionally
20 mixed with a binder, lubricant, inert diluent, or surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent. Ophthalmic inserts are made from compression molded films which are prepared on a Carver Press by subjecting the powdered
25 mixture of active ingredient and HPC to a compression force of 12,000 lb.(gauge) at 149 °C for 1-4 min. The film is cooled under pressure by having cold water circulate in the platen. The inserts are then individually cut from the film with a rod-shaped punch. Each insert is placed in a vial, which is then placed in a humidity cabinet (88%
30 relative humidity at 30 °C) for 2-4 days. After removal from the cabinet, the vials are capped and then autoclaved at 121 °C for .0.5 hr.

The following are representative pharmaceutical dosage forms of the compounds of Formula II:

	<u>I.M. Injectable Suspension</u>	<u>mg/mL</u>
	Compound of Formula II	10
	Methylcellulose	5
	Tween 80	0.5
5	Benzyl alcohol	9
	Benzalkonium chloride	1
	Water for injection to a total volume of 1 mL	
	<u>Tablet</u>	<u>mg/tablet</u>
	Compound of Formula II	25
10	Microcrystalline cellulose	415
	Povidone	14
	Pregelatinized starch	43.5
	Magnesium stearate	<u>2.5</u>
		500
15	<u>Capsule</u>	<u>mg/capsule</u>
	Compound of Formula II	25
	Lactose powder	573.5
	Magnesium stearate	<u>1.5</u>
		600
20	<u>Aerosol</u>	<u>Per canister</u>
	Compound of Formula II	24 mg
	Lecithin, NF liquid concentrate	1.2 mg
	Trichlorofluoromethane, NF	4.025 gm
	Dichlorodifluoromethane, NF	12.15 gm

	<u>Ophthalmic Solution</u>	<u>mg/mL</u>
	Compound of Formula II	1
	Monobasic sodium phosphate•2H ₂ O	9.38
	Dibasic sodium phosphate•12H ₂ O	28.48
5	Benzalkonium chloride	1
	Water for injection to a total volume of 1 mL	
	<u>Ophthalmic Suspension</u>	<u>mg/g</u>
	Compound of Formula II	1
	Petrolatum liquid to a total weight of 1 g	
10	<u>Ophthalmic Insert</u>	<u>mg/insert</u>
	Compound of Formula II	1
	Hydroxypropylcellulose	12

These compounds may also be used as libraries for discovering new lead structures by evaluation across an array of biological assays, including the discovery of selective inhibition patterns across isozymes. These libraries are thus tools for drug discovery; i.e., as a means to discover novel lead compounds by screening the libraries against a variety of biological targets and to develop structure-activity relationships in large families of related compounds. The libraries may be tested with the ligands attached to the solid supports as depicted in Formula I or the individual compounds II may be detached prior to evaluation. With the compounds of Formula I, screening assays such as FACS sorting and cell lawn assays may be used. When a compound is detached prior to evaluation, its relationship to its solid support is maintained, for example, by location within the grid of a standard 96-well plate or by location of activity on a lawn of cells. The solid support associated with bioactivity or the solid support related to the detached ligand may then be decoded to reveal the structural or synthetic history of the active compound (Ohlmeyer *et al.*, *Proc. Natl. Acad. Sci. USA*, 90, 10922-10926, Dec. 1993).

Assays for Determining Biological Activity

Xanthine Oxidase Inhibition - The following materials are used:

- 5 3.9 μ M hypoxanthine
- 0.3 mM 4-aminoantipyrene
- 2 mM 3,5-dichloro-2-hydroxybenzenesulfonate
- 50 mM sodium phosphate buffer, pH 7.5
- 5 U/mL horseradish peroxidase (Sigma P-6782, 5500 U/5 mg)
- 3 nM xanthine oxidase (buttermilk, Sigma X-4500, 16 U/mL)
- 10 inhibitor

- Reactions are carried out in 24 μ L total volume in 96-well U-bottom polypropylene microtiter dishes (Costar) containing the test compounds. 8 μ L of sodium phosphate buffer, pH 7.5, is added to each well. A substrate mixture is prepared on ice by mixing 0.53 mL sodium
- 15 phosphate buffer, 0.4 mL 4-aminoantipyrene (0.61 mg/mL), 0.4 mL
 - 3,5-dichloro-2-hydroxybenzene-sulfonate (5.3 mg/mL), 4 μ L
 - horseradish peroxidase (Sigma P-6782, 5500 U/5 mg), and 128 μ L
 - hypoxanthine 920 μ g/mL. 8 μ L of the substrate mixture is then pipetted
 - 20 into each well. 8 μ L xanthine oxidase (buttermilk, 9.0 nM, Sigma X-
 - 4500, 16 U/mL) in sodium phosphate buffer, pH 7.5 (or buffer alone as
 - a control) is added last, directly into the reaction mixture. The plates
 - are pulse-spun briefly in a tabletop centrifuge before reading
 - absorbance. Absorbance is read using a dual kinetics program (490
 - 25 minus 650 nm) for 15 min. at r.t. without automix, in a microplate
 - reader (Molecular Devices Thermomax). Initial rates are calculated
 - (Vmax program) and compared to those of reactions without inhibitor.

Other assays for evaluating the compounds of the present invention are well known in the art. Representative examples of references teaching these assays follow:

- 30 ACE Inhibition - Holmquist *et al.*, "A Continuous Spectrophotometric Assay for Angiotensin Converting Enzyme", *Anal. Biochem.*, 95, 540-548 (1979).

Thrombin Inhibition - Lottenberg *et al.*, "Assay of Coagulation Proteases Using Peptide Chromogenic and Fluorogenic Substrates", *Meth. in Enzymol.*, 80, 341-361, (1981).

- 5 Carbonic Anhydrase Inhibition - Maren and Couto, "The Nature of Anion Inhibition of Human Red Cell Carbonic Anhydrases", *Archiv. of Biochem. and Biophys.*, 196, No. 2, Sept., 501-510 (1979).

Carbonic Anhydrase Inhibition - Ponticello *et al.*, "Thienothiopyran-2-sulfonamides: A Novel Class of Water-Soluble Carbonic Anhydrase Inhibitors", *J. Med. Chem.*, 30, 591597 (11987).

10 Methods of Synthesis

- The compounds of the present invention can be prepared according to the following methods. At each step in the synthesis each solid support upon which a compound is being synthesized is uniquely tagged to define the particular chemical event(s) occurring during that
- 15 step. The tagging is accomplished using identifiers such as those of Formula IV, which record the sequential events to which the support is exposed during the synthesis, thus providing a reaction history for the compound produced on each support. The identifiers are used in combination with one another to form a binary or higher order
- 20 encoding scheme permitting a relatively small number of identifiers to encode a relatively large number of reaction products. For example, when used in a binary code, N identifiers can encode up to 2^N different compounds and/or conditions. By associating each variable or combination of variables at each step of the synthesis with a combination
- 25 of identifiers which uniquely define the chosen variables such as reactant, reagent, reaction conditions, or combinations of these, one can use the identifiers to define the reaction history of each solid support.

- In carrying out the syntheses, one begins with at least 10^3 , desirably at least 10^4 , and generally not exceeding 10^{15} solid supports.
- 30 Depending on the pre-determined number of R^1 choices for the first step, one divides the supports accordingly into as many containers. The appropriate reagents and reaction conditions are applied to each container and the combination of identifiers which encode for each R^1 choice is added and attached. Depending on the chemistries involved,

the tagging may be done prior to, concomitantly with, or after the reactions which comprise each choice. As a control, sample supports may be picked at any stage and a portion of their tags detached and decoded to verify that the correct tags are bound to the sample supports.

- 5 As needed, one may wash the beads free of any excess reagents or by-products before proceeding. At the end of each step, the supports are combined, mixed, and again divided, this time into as many containers as pre determined for the number of A choices for the second step in the synthesis. This procedure of dividing, reacting, tagging, and
10 remixing is repeated until the combinatorial synthesis is completed.

Scheme 1

- Functionalized supports such as amino-functionalized or hydroxy-terminating PEG grafted polystyrene beads are equally divided into a pre-determined number of reaction vessels and are reacted with
15 either a) a cleavable linker/ligand element which has been pre-formed to generate 2 when the detached ligand element terminates in OH or b) a cleavable linker, followed by reaction with a ligand element to generate 3 in the case when the detached ligand element terminates in COOH. Compounds 2 and 3 are then treated with piperidine/DMF to de-protect
20 the amino group of the ligand element R¹ to yield 4 (Scheme 1, step (c)). Unique tagging of the supports in each reaction vessel is achieved with combinations of identifiers encoded in a binary scheme, e.g., as depicted in Table 1-1 for seven choices of R¹. The identifiers are attached by adding a solution of the identifiers (in a 5% wt./wt.
25 identifier:solid support ratio) to a batch of supports suspended in CH₂Cl₂ and shaking the mixture for 30 min. A dilute solution of rhodium trifluoroacetate dimer is added and the mixture is immediately shaken. The mixture is continued to be shaken overnight and the washed in CH₂Cl₂.

Scheme 2







The compounds 4 are pooled, mixed, and then divided into a pre-determined number of reaction vessels, each of which is treated with one reagent corresponding to ligand element A, in the presence of
5 HOBt/DMF to produce 5. The reaction vessels are then treated with piperidine/DMF to de-protect the terminal amino group, yielding 6. Unique tagging of the supports in each reaction vessel is achieved with combinations of additional identifiers encoded in a binary scheme, e.g., as depicted in Table 1-2 for 31 choices of A.

10 Scheme 3

The compounds 6 are pooled, mixed, and then divided into a pre-determined number of reaction vessels each of which is treated with one reagent corresponding to ligand element Y in the presence of solvents such as CH₂Cl₂ and DMF, and, when required, condensation
15 reagents such as DIC, acylation catalysts such as DMAP, and bases such as triethylamine to produce 7. Unique tagging of the supports in each reaction vessel is achieved with combinations of additional identifiers encoded in a binary scheme, e.g., as in Table 1-3 for 31 choices of Y. Compound 7 is then either exposed to UV light (~360 nm) in a lower
20 alkanol such as MeOH to cleave the protected form of the compounds of Formula II from the support/linker complex or first treated with TFA/thioanisole/EDT to remove the protecting groups on the R² sidechains and then exposed to UV light in a lower alkanol such as MeOH to cleave compound II.


SCHEME 1
ADDITION OF R¹

a. Carbonate-linked Moieties


R¹ =

SCHEME 1 (Cont.)


b. Ester-linked Moieties




c. Fmoc Deprotection



* where R¹ includes the
carbonate linkage in 2 and
the ester linkage in 3

SCHEME 2
ADDITION OF A

(Prot) = optional, non-Fmoc, base stable sidechain protecting group

SCHEME 3
ADDITION OF Y

Representative Compounds

Table 2 illustrates compounds of Formula II which are representative of the present invention:



TABLE 2
REPRESENTATIVE COMPOUNDS









Y	A	R ¹
1. 	-NH(CH ₂) ₂ -	-NH(CH ₂) ₂ O(CH ₂) ₄ OH
2. 	-NH(CH ₂) ₃ -	-NH(CH ₂) ₃ COOH
3. 	-NH(CH ₂) ₅ -	-NH(CH ₂) ₄ OH
4. 	-NH(CH ₂) ₁₀ -	
5. 		

TABLE 2 (Cont.)

6.			
7.			
8.			
9.			
10.			

Table 3 illustrates additional compounds of Formula II representative of the present invention which are inhibitors of carbonic anhydrase:



TABLE 3
REPRESENTATIVE COMPOUNDS

5

10

15

20

25

30










Y	A	R ¹
1. 	$-NH-CH-(L)-CH(CH_3)_2$	
2. 	$-NH-CH-(L)-Ph$	
3. 	$(CH_2)_2-COOH$ $-NH-CH-(L)-$	
4. 	$-NH-(CH_2)_5-$	
5. 	$-NH-CH-(L)-Ph$	$-NH-(CH_2)_5-COOH$

Table 3 (Cont.)

5	6.		$\text{-NHCH-CH(CH}_3)_2$ (L)	
10	7.		-NHCH-Ph (L)	
15	8.		-NHCH-CH_3 (D)	$\text{-NH-(CH}_2)_5\text{-COOH}$
20	9.		-NHCH-COOH (D)	
25	10.		-NHCH-CH_3 (D)	
30	11.		-NHCH-COOH (D)	

Table 3 (Cont.)

5	12.			
	13.		$\begin{array}{c} \text{CH}(\text{CH}_3)_2 \\ \\ \text{-NH-CH-} \\ \text{(L)} \end{array}$	$\begin{array}{c} \text{-N-(CH}_2\text{)}_2\text{-O-(CH}_2\text{)}_2\text{-OH} \\ \text{H} \end{array}$
10	14.		$\begin{array}{c} (\text{CH}_2)_2\text{-COOH} \\ \\ \text{-NH-CH-} \\ \text{(L)} \end{array}$	$\text{-NH-(CH}_2\text{)}_5\text{-COOH}$
15	15.		$\begin{array}{c} \text{CH}_2\text{C(O)NH}_2 \\ \\ \text{-NHCH-} \\ \text{(L)} \end{array}$	$\begin{array}{c} \text{-N-(CH}_2\text{)}_2\text{-O-(CH}_2\text{)}_2\text{-OH} \\ \text{H} \end{array}$
20	16.		$\begin{array}{c} \text{CH}_2\text{CO}_2\text{H} \\ \\ \text{-NHCH-} \\ \text{(D)} \end{array}$	$\begin{array}{c} \text{-N-(CH}_2\text{)}_2\text{-O-(CH}_2\text{)}_2\text{-OH} \\ \text{H} \end{array}$
25	17.		$\begin{array}{c} \text{CH}_2\text{CO}_2\text{H} \\ \\ \text{-NHCH-} \\ \text{(D)} \end{array}$	
30	18.		$\begin{array}{c} \text{CH}(\text{CH}_3)_2 \\ \\ \text{-NHCH-} \\ \text{(D)} \end{array}$	$\begin{array}{c} \text{-N-(CH}_2\text{)}_2\text{-O-(CH}_2\text{)}_2\text{-OH} \\ \text{H} \end{array}$

Table 3 (Cont.)

19.		$\text{CH}_2\text{CH}_2\text{SCH}_3$ $-\text{NHCH}-$ (D)	
20.		$-\text{NH}(\text{CH}_2)_6-$	$-\text{N}-(\text{CH}_2)_2-\text{O}-(\text{CH}_2)_2-\text{OH}$ H
21.		$\text{H}_3\text{C}-\text{CHCH}_2\text{CH}_3$ $-\text{NHCH}-$ (L)	
22.		$(\text{CH}_2)_2\text{CO}_2\text{H}$ $-\text{NHCH}-$ (D)	
23.		$\text{CH}(\text{CH}_3)_2$ $-\text{NHCH}-$ (D)	
24.		$\text{CH}_2\text{CH}(\text{CH}_3)_2$ $-\text{NHCH}-$ (L)	
25.			

Table 3 (Cont.)

26.		$\begin{array}{c} \text{CH}_2\text{CH}(\text{CH}_3)_2 \\ \\ \text{-NHCH-} \\ (\text{L}) \end{array}$	$\text{-NH-(CH}_2)_5\text{-COOH}$
27.		$\begin{array}{c} \text{-NHCH-} \\ \\ \text{Imidazole ring} \end{array}$ (D)	
28.		$\begin{array}{c} \text{Ph} \\ \\ \text{-NHCH-} \\ (\text{L}) \end{array}$	
29.		$\begin{array}{c} \text{COOH} \\ \\ \text{-NHCH-} \\ (\text{L}) \end{array}$	
30.		$\begin{array}{c} \text{C(O)NH}_2 \\ \\ \text{-NHCH-} \\ (\text{L}) \end{array}$	$\text{-NH-(CH}_2)_5\text{-COOH}$
31.		$\text{-NH(CH}_2)_5\text{-}$	
32.		$\begin{array}{c} \text{CH}_3 \\ \\ \text{-NHCH-} \\ (\text{D}) \end{array}$	$\text{-N-(CH}_2)_2\text{-O-(CH}_2)_2\text{-OH}$ H

Table 3 (Cont.)


33.		$(\text{CH}_2)_2\text{CO}_2\text{H}$ $-\text{NHCH}-$ (D)	$-\text{N}-(\text{CH}_2)_2-\text{O}-(\text{CH}_2)_2-\text{OH}$ H
34.		$(\text{CH}_2)_2\text{C}(\text{O})\text{NH}_2$ $-\text{NHCH}-$ (D)	
35.		$(\text{CH}_2)_2\text{C}(\text{O})\text{NH}_2$ $-\text{NHCH}-$ (L)	$-\text{N}-(\text{CH}_2)_2-\text{O}-(\text{CH}_2)_2-\text{OH}$ H
36.		$(\text{CH}_2)_2\text{CO}_2\text{H}$ $-\text{NHCH}-$ (L)	$-\text{N}-(\text{CH}_2)_2-\text{O}-(\text{CH}_2)_2-\text{OH}$ H

The invention is further defined by reference to the following examples, which are intended to be illustrative and not limiting.

PREPARATION 1

IDENTIFIERS

Thirteen compounds of the general formula:



wherein:

$n = 3-12$ and Ar is pentachlorophenyl or

n = 4-6 and Ar is 2,4,6-trichlorophenyl were prepared according to Scheme 4 and the following illustrative example.

5 a) Methyl vanillate (0.729 g, 4.0 mmole), 1-hydroxy-9-(2,3,4,5,6-pentachlorophenoxy)nonane (1.634 g, 4.0 mmole) and triphenylphosphine (1.258 g, 4.8 mmole) were dissolved in 20 mL dry toluene under argon. DEAD (0.76 mL, 0.836 g, 4.8 mmole) was added dropwise and the mixture was stirred at 25°C for one hr. The solution was concentrated to half volume and purified by flash chromatography
10 eluting with DMC to give 1.0 g (1.7 mmole, 43%) of the product as a white crystalline solid.

b) The methyl ester from Step (a) (1.0 g, 1.7 mmole) was dissolved in 50 mL THF, 2 mL water was added, followed by LiOH (1.2 g, 50 mmole). The mixture was stirred at 25°C for one hr. then
15 refluxed for 5 hr. After cooling to 25°C, the mixture was poured onto ethyl acetate (200 mL) and the solution was washed with 1 M HCl (3x 50 mL) then sat'd aq. NaCl (1x 50 mL) and dried over sodium sulfate. The solvent was removed and the crude acid azeotroped once with toluene.

20 c) The crude material from Step (b) was dissolved in 100 mL toluene, 10 mL (1.63 g, 14 mmole) thionyl chloride was added, and the mixture was refluxed for 90 min. The volume of the solution was reduced to approx. 30 mL by distillation, then the remaining toluene was removed by evaporation. The crude acid chloride was
25 dissolved in 20 mL dry DCM and cooled to -70°C under argon and a solution of approx. 10 mmole diazomethane in 50 mL anhydrous ether was added. The mixture was warmed to r.t. and stirred for 90 min. Argon was bubbled through the solution for 10 min., then the solvents were removed by evaporation and the crude material was purified by
30 flash chromatography, eluting with 10-20% ethyl acetate in hexane. The diazoketone (0.85 g, 1.4 mmole, 82% yield over three steps) was obtained as a pale yellow solid.

35 An improvement was made to the final diazomethylation step, whereby the acid chloride was reacted with (trimethylsilyl)diazomethane and triethylamine to give the identifier,


which was then used without further purification. This was a significant improvement over the original reaction with diazomethane, as the identifier was now obtained in high yield with no chloromethylketone byproduct. Also, purification by flash chromatography was no longer
5 necessary, which in some cases had resulted in significant acid-catalyzed decomposition of the identifier.

Alternate Step c) To a solution of the acyl chloride (3.8 mmol, 1.00 eq.) and 1.85 mL (13.3 mmol, 3.50 eq.) of triethylamine in anhydrous THF/acetonitrile (1:1) at 0°C under argon was added 5.7 mL
10 (11.4 mmol, 3.00 eq.) of a 2.0 M solution of (trimethylsilyl)diazomethane in hexanes. The resulting orange solution was stirred at 0°C for 2 hr, then at 25°C for 17 hr. (If a precipitate formed immediately upon addition of (trimethylsilyl)diazomethane, CH₂Cl₂ was added until the precipitate redissolved). EtOAc was added
15 (250 mL), and the organic layer washed with saturated aq. NaHCO₃ (100 mL) and H₂O (100 mL), then dried (anhydrous MgSO₄). Removal of the volatiles in vacuo gave the product as yellow crystals in 60-100% yield.

The other 12 identifiers of Formula IV were prepared by
20 analogous synthetic routes, steps (a), (b), and (c).

In the synthesis of Example 1, the 13 identifiers were used to encode the combinatorial library. In Step 1, pentachlorophenyl identifiers where n = 10-12 (abbreviated C₁₀Cl₅, C₁₁Cl₅, and C₁₂Cl₅) were used in the following binary encoding scheme: 001 = (n = 12),
25 010 = (n = 11) and 100 = (n = 10). In Step 2, pentachlorophenyl identifiers where n = 5-9 (abbreviated C₅Cl₅, C₆Cl₅, C₇Cl₅, C₈Cl₅, and C₉Cl₅) were used and encoded as follows: 00001 = (n = 9), 00010 = (n = 8), 00100 = (n = 7), 01000 = (n = 6) and 10000 = (n = 5). In Step 3, pentachlorophenyl identifiers where n = 3-4 (abbreviated C₃Cl₅ and
30 C₄Cl₅) were used and encoded as follows: 00001 = (n = 4), 00010 = (n = 3). Also in Step 3, trichlorophenyl identifiers where n = 4-6 (abbreviated C₄Cl₃, C₅Cl₃, and C₆Cl₃) were used and encoded as follows: 00100 = (n = 6), 01000 = (n = 5), and 10000 = (n = 4).

Thus, in Step 1 reagent 3 (Table 1-1) is encoded "011" which represents tagging this choice in the synthesis with the two pentachloro-phenyl identifiers where $n = 11$ and 12 . Likewise, in Step 3 reagent 52 (Table 1-3) is encoded "01110" which represents tagging this choice in the synthesis with the pentachlorophenyl identifier where $n = 3$ and the two trichlorophenyl identifiers where $n = 5$ and 6 .

SCHEME 4
IDENTIFIERS


PREPARATION 2
t-BUTYL-4-(HYDROXYMETHYL)-3-NITROBENZOATE

- t-Butyl 4-(acetoxymethyl)-3-nitrobenzoate was prepared as described by Barany and Albericio, *J. Am. Chem. Soc.* **1985**, *107*, 4936-4942. However, attempts to also follow the reference's final procedure for hydrazinolysis of the acetate using hydrazine hydrate in CHCl_3 at 25°C produced only trace amounts of the desired hydroxymethyl final product, which is the t-butyl ester pre-cursor of the photocleavable linker used herein. It has now been found that hydrazinolysis using hydrazine hydrate in MeOH or DMF at 25°C produces t-butyl 4-(hydroxymethyl)-3-nitrobenzoate in high yield but that a byproduct produced in DMF by additional diimide reduction of the nitro functionality to an amino group makes this solvent undesirable. Using MeOH as solvent, only the desired final product was obtained in near quantitative yield.

This new hydrazinolysis procedure was also used to produce the photocleavable linker when attached to TentaGel S NH_2 resin.

- t-Butyl 4-(hydroxymethyl)-3-nitrobenzoate: To a solution of 14.1 g (47.7 mmol, 1.00 eq.) of t-butyl 4-(acetoxymethyl)-3-nitrobenzoate in MeOH (200 mL) was added 27.0 mL (477 mmol, 10.0 eq.) of hydrazine hydrate (55% hydrazine). The resulting yellow solution was stirred at 25°C for 4 hr. EtOAc (250 mL) and saturated aq. NaCl (85 mL) were added, and the organic layer collected after shaking. The organic layer was washed further with saturated aq. NaCl (2 x 85 mL), and then dried (MgSO_4). Removal of volatiles in vacuo gave the product in 93% yield as yellow crystals.
- TentaGel S NH_2 - attached 4-(hydroxymethyl)-3-nitrobenzamide: See Example 1, Step 1a.

The reaction is represented in Scheme 5.

SCHEME 5
HYDRAZINOLYSISEXAMPLE 16727 COMPOUND LIBRARYStep 1

a) Preparation of ester-linked resin batches

TentaGel SNH₂, (10 g, 2.9 mmole, 0.29 mmole/g) was suspended in 60 mL methylenechloride. 4-acetoxymethyl-3-nitrobenzoic acid (2.77 g, 11.6 mmole, 4 eq), DMAP (1.42 g, 11.6 mmole, 4 eq) and DIC (1.81 mL, 1.46 g, 11.6 mmole, 4 eq) was added in that order. The mixture was agitated at 25 °C with a wrist action shaker for 5 hours, at which time the resin gave a negative Kaiser test. The derivatized resin was washed (methylenechloride 5 x 50 mL, isopropanol 5 x 50 mL, then methylenechloride 5 x 50 mL), dried in vacuo and stored in the dark.

The acetoxymethyl resin above was washed with methanol (1 x 150 mL), then suspended in 150 mL 10% hydrazine/methanol. The resin was agitated at 25 °C for 44 hours, filtered, then washed (methanol, 5 x 100 mL, then methylene chloride, 5 x 100 mL) and dried in vacuo.

Three batches of the above hydroxymethyl resin (3 g each, 0.84 mmole, 0.28 mmole/g) were placed in 100 mL synthesis vessels and each was suspended in 60 mL dichloromethane. One of N-Fmoc isonipecotic acid (0.885 g, 2.52 mmole, 3 eq), N-Fmoc nipecotic acid

(0.885 g, 2.52 mmole, 3 eq), and N-Fmoc- ϵ -amino caproic acid (0.890 g, 2.52 mmole, 3 eq) was added to each of the three batches. DMAP (0.031 g, 0.252 mmole, 0.3 eq) and then DIC (0.4 mL, 0.318 g, 2.52 mmole, 3 eq) was added to each and the resin batches were agitated at 25 °C for 22 hours. The resin batches were filtered, washed (methylenedichloride (5 x 50 mL) and isopropanol (2 x 50 mL), then methylenedichloride (5 x 50 mL)), and dried in vacuo.

b) Preparation of carbonate-linked resin batches

N-Fmoc-2-hydroxymethylpiperidine (1.35 g, 4 mmole, 1 eq) was dissolved in 20 mL methylenedichloride and cooled to 0 °C. Phosgene (8 mL, 2 M solution in toluene, 16 mmole, 4 eq) was added followed by 2,6-lutidine (1.86 mL, 1.71 g, 4 eq), then the mixture was stirred for 30 min. The mixture was concentrated on a rotary evaporator to give a viscous slurry and this residue was redissolved in 30 mL methylenedichloride (the solution contained some undissolved solid). ^tButyl 4-hydroxymethyl-3-nitrobenzoate (0.51 g, 2 mmole, 0.5 eq) was added and the mixture was stirred at 25 °C for 2 hours. The crude reaction mixture was poured onto 200 mL ethyl acetate and this solution was washed with 1 M HCl (2 x 100 mL), sat'd aq. NaHCO₃ (2 x 100 mL) and sat'd aq. NaCl (1 x 100 mL). The solution was dried over magnesium sulfate, filtered, and evaporated to give the crude product. This was purified by flash chromatography eluting with 10-30% ethylacetate/hexane to give the product (1.22 g, 1.97 mmole, 99%) as a pale yellow solid.

The carbonate above was dissolved in 20 mL methylene chloride, 10 mL TFA was added and the mixture was stirred at 25 °C for 16 hours. The solution was diluted with 50 mL toluene and evaporated to give the carboxylic acid as a viscous yellow oil which was azeotroped with toluene once, then dried in vacuo.

The acid prepared above (~2 mmole, 2 eq) was dissolved in 30 mL methylenedichloride and this solution was added to TentaGel S NH₂ (3 g, 0.32 mmole/g, ~1 mmole, 1 eq). The resin was suspended by agitation then DMAP (40 mg, 0.3 mmole, 0.3 eq) and DIC (0.47 mL, 0.4 g, 3 eq) were added in that order. The resin was agitated at 25 °C for 19 hours, at which time it gave a negative Kaiser test. The resin

was filtered and washed (methylenchloride 10 x 50 mL), then dried in vacuo.

The three other carbonate linked resin batches were prepared in an analogous manner using the reagents of Table 1-1.

5 c) Encoding of Step 1

One gram batches of the seven resin batches from Steps 1(a) and 1(b) with the appropriately linked N-Fmoc protected amino acid or amino alcohol were placed in seven separate synthesis vessels and each was suspended in 20 mL methylene chloride.

10 Stock solutions of 200 mg of C₁₂Cl₅, C₁₁Cl₅, and C₁₀Cl₅-linker-diazoketone (Preparation 1) were prepared in 4 mL methylenchloride. Aliquots (1 mL) of the stock solutions were used to prepare the appropriate binary coding mixtures for each of the seven resin batches. The appropriate coding mixture was added to each resin
15 batch and the resin was agitated for 1 hour. Rhodium trifluoroacetate dimer (1 mL of a 1 mg/mL solution in methylenchloride) was added to each of the vessels and the resin was agitated at 25 °C overnight. Each resin batch was washed with methylenchloride (1 x 50 mL), then the batches were combined and the entire library (seven compounds) was
20 washed with methylenchloride (10 x 50 mL).

d) Deprotection

N-Fmoc protecting groups were removed by washing the resin once with DMF, filtering, then suspending the resin in 60 mL 50%
25 piperidine/DMF and agitating at room temperature for 30 min. The resin was filtered, washed (DMF (5 x 50 mL) and methylenchloride (10 x 50 mL)) and dried in vacuo.

Step 2

a) Addition of A

30 The dried resin from Step 1(d) was divided into 31 batches of 210 mg (~0.07 mmole), each of which was placed in a 20 mL synthesis vessel. Each of the reagents (0.25 g, > 0.4 mmole, > 6 eq) (Table 1-2) used in the second step of the synthesis (N-Fmoc amino acid with acid labile side chain protection where appropriate) was dissolved in 10 mL
35 methylenchloride. HOBt (1 mL of 1 mg/mL in DMF) was added and

the solutions were shaken briefly. Further DMF was added to those amino acids that had not completely dissolved. Each reagent solution was added to one of the 31 resin batches. DIC (0.2 mL, ~1 mmole) was added to each vessel and the resin was agitated at 25 °C overnight.

- 5 Each of the resin batches was filtered and washed separately (DMF (1 x 15 mL) and methylenechloride (10 x 15 mL)). The resin was suspended in 10 mL methylenechloride.

b) Encoding of Step 2

- 10 Stock solutions of 160 mg of C₉Cl₅, C₈Cl₅, C₇Cl₅, C₆Cl₅, and C₅Cl₅ -linker-diazoketone (Preparation 1) were prepared in 16 mL methylenechloride. Aliquots (1 mL) of the stock solutions were used to prepare the appropriate binary coding mixtures for each of the 31 resin batches (Table 1-2). The appropriate coding mixture was added to each of the resin batches and the resin was agitated for 30 min. Rhodium
- 15 trifluoroacetate dimer (1 mL of a 1 mg/mL solution in methylenechloride) was added to each of the vessels and the resin was agitated at 25 °C overnight. Each resin batch was filtered then washed separately with methylenechloride (1 x 15 mL). The batches were combined and the entire library (217 compounds) was washed with
- 20 methylenechloride (5 x 50 mL).

c) Deprotection

- N-Fmoc protecting groups were removed by washing the resin once with DMF, filtering, then suspending the resin in 60 mL 50% piperidine/DMF and agitating at room temperature for 30 min. The
- 25 resin was filtered, washed (DMF (5 x 50 mL) and methylenechloride (10 x 50 mL)) and dried in vacuo.

Step 3

a) Addition of Y

The dried resin from Step 2 (c) was divided into 31 batches of 150 mg (~ 0.05 mmole), each of which was placed in a 20 mL synthesis vessel. Each of the reagents (0.25 g, > 0.4 mmole, > 8 eq) used in the third step of the synthesis was dissolved in methylenechloride or DMF or a mixture of the two as appropriate (Table 1-3). Each reagent solution was added to one of the 31 resin batches, then any coreagents were added as required (see table). The resin batches were agitated at 25 °C overnight, then each was washed (DMF (1 x 10 mL) and methylenechloride (10 x 10 mL)).

b) Encoding of Step 3

Stock solutions of 200 mg of C_4Cl_5 and C_3Cl_5 -linker-diazoketone (Preparation 1) were prepared in 16 mL methylenechloride. Stock solutions of 600 mg of C_6Cl_3 , C_5Cl_3 , and C_4Cl_3 -linker-diazoketone (Preparation 1) were prepared in 16 mL methylenechloride. Aliquots (1 mL) of the stock solutions were used to prepare the appropriate binary coding mixtures for each of the 31 resin batches (Table 1-3). The appropriate coding mixture was added to each of the resin batches and the resin was agitated for 30 min. Rhodium trifluoroacetate dimer (1 mL of a 1 mg/mL solution in methylenechloride) was added to each of the vessels and the resin was agitated at 25 °C overnight. Each resin batch was filtered then washed separately with methylenechloride (1 x 15 mL). The batches were combined and the entire library (6727 compounds) was washed with methylenechloride (5 x 50 mL), then dried in vacuo.

c) Deprotection

The combined resins from Step 3(b) (~ 2 g) were suspended in 60 mL TFA/thioanisole/EDT (50/50/5) and shaken at room temperature overnight. The resins were filtered, washed (methylenechloride 10 x 50 mL), and dried in vacuo.

d) Decoding Procedure

A bead is placed in a 1.3 mm diameter pyrex capillary with 2 μ L of acetonitrile. Ceric ammonium nitrate solution (2 μ L of a 0.1 M aq.

solution) and hexane (3 μ L) are added and the two-phase mixture centrifuged briefly. The tube is sealed and left at 35 °C for 16 hrs, then opened. The organic layer is removed by syringe and mixed with 1 μ L of N,O-bis(trimethylsilyl)acetamide. The silylated tag solution (1 μ L) is
5 analyzed by GC with electron capture (EC) detection.

The GC analysis is performed with a Hewlett Packard 5890 plus gas chromatograph. On column injection into a 5 m, 0.32 mm retention gap connected to a 25 m, 0.2 mm crosslinked 5% phenylmethyl silicone column is used. The temperature and pressure programs for the
10 analysis are 200-320 °C, 15 °C/min, then 320 °C for 10 min and 20-40 psi at 2 psi/min, then 40 psi for 10 min. The EC detector is maintained at 400 °C and the auxiliary gas is set at 35 psi.

Table 1-1
R¹ Residues and Encoding Scheme

R ¹ Residue	Binary Code
1.	001
2.	010
3.	011
4.	100
5.	101
6.	110
7.	111

Table 1-2

R² Reagents and Encoding Scheme







Reagent	Binary Code
8.  (L)	00001
9.  (D)	00010
10.  (D)	00011
11.  (L)	00100
12.  (L)	00101
13.  (L)	00110

Table 1-2 (Cont.)








14.	 (D)	00111
15.	 (D)	01000
16.	 (L)	01001
17.		01010
18.	 (D)	01011
19.	 (L)	01100
20.	 (L)	01101

Table 1-2 (Cont.)








21.	 (D)	01110
22.	 (L)	01111
23.	 (D)	10000
24.	 (D)	10001
25.	 (L)	10010
26.	 (L)	10011
27.	 (D)	10100

Table 1-2 (Cont.)








5	28.		10101
10	29.		10110
15	30.		10111
20	31.		11000
25	32.		11001
30	33.		11010
	34.		11011

Table 1-2 (Cont.)





35.	 (L)	11100
36.	 (D)	11101
37.		11110
38.		11111

Table 1-3

Y Reagents and Encoding Scheme






5	Y Reagent	Solvent	Co-reagent(s)	Binary Code
10	39. 	DMF	0.3 mL DIC, 100 mg DMAP	00001
15	40. 	DMF	0.3 mL DIC, 100 mg DMAP	00010
20	41. 	DMF	0.3 mL DIC, 100 mg DMAP	00011
25	42. 	CH ₂ Cl ₂	0.5 mL NEt ₃ , 100 mg DMAP	00100
30	43. 	CH ₂ Cl ₂	0.5 mL NEt ₃ , 100 mg DMAP	00101

Table 1-3 (Cont.)







5	44.		CH ₂ Cl ₂	0.5 mL NEt ₃ , 100 mg DMAP	00110
10	45.		CH ₂ Cl ₂	0.5 mL NEt ₃ , 100 mg DMAP	00111
15	46.		CH ₂ Cl ₂	0.5 mL NEt ₃ , 100 mg DMAP	01000
20	47.		CH ₂ Cl ₂ /DMF (1:1)	0.5 mL NEt ₃ , 100 mg DMAP	01001
25	48.	n-BuSO ₂ Cl	CH ₂ Cl ₂	0.5 mL NEt ₃ , 100 mg DMAP	01010
	49.		CH ₂ Cl ₂	0.5 mL NEt ₃ , 100 mg DMAP	01011
30	50.		CH ₂ Cl ₂	0.5 mL NEt ₃ , 100 mg DMAP	01100

Table 1-3 (Cont.)








51.		CH ₂ Cl ₂	0.5 mL NEt ₃ , 100 mg DMAP	01101
52.		CH ₂ Cl ₂	0.3 mL DIC, 100 mg DMAP	01110
53.		CH ₂ Cl ₂ /DMF (1:1)	0.3 mL DIC, 100 mg DMAP	01111
54.		CH ₂ Cl ₂ /DMF (1:1)	0.3 mL DIC, 100 mg DMAP	10000
55.		CH ₂ Cl ₂	100 mg DMAP	10001
56.		CH ₂ Cl ₂ /DMF (1:1)	0.3 mL DIC, 100 mg DMAP	10010
57.	MeO(CH ₂) ₅ CO ₂ H	CH ₂ Cl ₂	0.3 mL DIC, 100 mg DMAP	10011
58.		CH ₂ Cl ₂	0.3 mL DIC, 100 mg DMAP	10100

Table 1-3 (Cont.)











	59. $\text{H}_3\text{C}-\text{CH}_2-\text{CO}_2\text{H}$	CH_2Cl_2	0.3 mL DIC, 100 mg DMAP	10101
5	60. 	$\text{CH}_2\text{Cl}_2/\text{DMF}$ (1:1)	0.3 mL DIC, 100 mg DMAP	10110
10	61. 	$\text{CH}_2\text{Cl}_2/\text{DMF}$ (1:1)	0.3 mL DIC, 100 mg DMAP	10111
15	62. 	$\text{CH}_2\text{Cl}_2/\text{DMF}$ (1:1)	0.3 mL DIC, 100 mg DMAP	11000
20	63. 	CH_2Cl_2		11001
	64. 	CH_2Cl_2		11010
25	65. 	CH_2Cl_2	0.5 mL NEt_3	11011
30	66. 	CH_2Cl_2		11100


Table 1-3 (Cont.)

5	67. 	Fmoc-G-OH, DIC, DMAP DMF, then piperidine/ DMF	2-Napthalene- sulfonyl chloride, NEt ₃ , DMAP, CH ₂ Cl ₂	11101
10	68. 	Fmoc-G-OH, DIC, DMAP DMF, then piperidine/ DMF	4-Biphenyl- carboxylic acid, DIC, DMAP, CH ₂ Cl ₂ /DMF	11110
15	69. 	Fmoc-G-OH, DIC, DMAP DMF, then piperidine/ DMF	Imidazole- acetic acid, DIC, DMAP, CH ₂ Cl ₂ /DMF	11111

EXAMPLE 2

DVB-CROSSLINKED VS. PEG-GRAFTED
POLYSTYRENE SOLID SUPPORTS

A compound of Formula II of the structure V:



30

was synthesized essentially as described in Example 1, but without the addition of identifiers. The synthesis was carried out using both 100 μ m 1% DVB-crosslinked polystyrene beads and 130 μ m DVB-crosslinked, PEG-grafted polystyrene beads. At the end of each step, the ligand, or intermediate ligand, was cleaved from a portion of the beads. At the end of Step 3, a portion of the ligand on the PEG-grafted support was

cleaved while still protected and another portion was de-protected prior to cleavage. The ligand on the DVB-crosslinked support was de-protected prior to cleavage. Table 2-1 presents the yield data for both syntheses. The yields were calculated based on the available
5 functionalities (~300 pmole) on each bead.

Table 2-1
Comparative Yields

	DVB Polystyrene (%)	PEG Polystyrene (%)
Step 1	49	85
Step 2	31	45
Step 3 - Protected		58
De-protected	8	61

WHAT IS CLAIMED IS:

1. A compound of the formula:




wherein:

- 5 \textcircled{S} is a solid support;
 T'-L- is an identifier residue;
 -L'-II' is a ligand/linker residue; and
 q is 3-30.


2. A compound of Claim 1 wherein:

10 T'-L- is of the Formula:



wherein n = 3-12 when Ar is pentachlorophenyl and
 n = 4-6 when Ar is 2,4,6-trichlorophenyl;
 3-13; and

15 q is
 -L'- is




wherein the left-hand bond as shown is the point of attachment to the solid support and the right hand bond is the point of attachment to the ligand, and B is O or NH, with the proviso that in (b) B is NH when attached to a carbonyl group in the ligand.

3. A compound of the formula:



wherein:


R^1 is $-\text{N}(\text{R}^6)-(\text{CH}_2)_{2-5}-\text{Z}-(\text{CH}_2)_{2-5}-\text{R}^9$, $-\text{NH}(\text{CH}_2)_{2-5}-\text{R}^9$, or





10 R^2 is the residue on the α carbon of methionine, O-t-butyl-serine, serine, S-trityl-cysteine, cysteine, aspartic acid- β -t-butyl ester, aspartic acid, glutamic acid- γ -t-butyl ester, glutamic acid, N^{im} -trityl-histidine, histidine, N^{ϵ} -Boc-lysine, lysine, N^{g} -Mtr-arginine, arginine, N^{β} -trityl-asparagine, asparagine, N^{γ} -trityl-glutamine, glutamine, N^{in} -Boc-tryptophan, tryptophan, isoleucine, phenylalanine, glycine, alanine, valine, or leucine;

15 R^3 is lower alkyl or $-(\text{CH}_2)_m\text{-Q-X}$, with the proviso that when $m = 0$, R^{10} is not OH;

R^4 is $-\text{Q}(\text{R}^7, \text{R}^8)\text{-SO}_2\text{NH}_2$, $-(\text{CH}_2)_m\text{-R}^{10}$, with the proviso that when $m = 0$, R^{10} is not OH, lower alkyl, a 6-membered aromatic heterocyclic ring containing 1 or 2 N atoms, heteroaryl-lower alkyl,



- R⁵** is lower alkyl, lower cycloalkyl, alkenyl, alkynyl, a mono- or bicyclic 6- to 10-membered aromatic ring system, or a mono- or bicyclic 5- to 10-membered heteroaromatic ring system containing 1 or 2 N atoms, either system unsubstituted or substituted with 1-2 substituents selected from halogen, alkoxy, alkyl, CF₃, CN, -N(lower alkyl)₂, and acylamino;
- R⁶** is H or lower alkyl;
- R⁷, R⁸** is each independently H, halogen, lower alkyl, alkoxy, CN, -NO₂, -CO-lower alkyl, -N(lower alkyl)₂, or NH-CO-lower alkyl;
- R⁹** is OH, CONH₂, or COOH;
- R¹⁰** is alkoxy, OH, or COOH;
- m** is 0-6;
- A** is -NH-CHR²-, -NH(CH₂)₂₋₁₂-, , , or the decarboxy residue of a primary or secondary amino acid;
- Q** is a 5- or 6-membered aromatic or heteroaromatic ring containing 0-3 heteroatoms selected from O, N, and S, or a bicyclic 9- or 10-membered aromatic or heteroaromatic ring system containing 0-3 heteroatoms selected from O, N, and S;

-63-

X is H, lower alkyl, halogen, alkoxy, CF_3 , CN, $-\text{NO}_2$, $-\text{CO}$ -lower alkyl, $-\text{N}(\text{lower alkyl})_2$, $\text{NH}-\text{CO}$ -lower alkyl, or COOH ;


Y is $-\text{SO}_2\text{R}^3$, $-\text{COR}^4$, $-\text{CO}-\text{CH}(\text{R}^2)-\text{NHSO}_2\text{R}^3$,
 5 $-\text{CO}-\text{CH}(\text{R}^2)-\text{NHCOR}^4$, $-\text{CO}-\text{NHR}^5$, or $-\text{COOR}^5$; and

Z is $-\text{O}-$, $-\text{S}-$, or $-\text{N}(\text{lower alkyl})-$;


or a pharmaceutically acceptable salt thereof.

4. A compound of Claim 3 wherein:

Y is




15 A is $-\text{NH}-\text{CHR}^2-$, $-\text{NH}(\text{CH}_2)_{2-12}-$, $-\text{N}-$ (pyrrolidine), $-\text{N}-$ (piperidine),
 or the decarboxy residue of a primary or secondary amino acid; and

R¹ is

5. A compound of Claim 3 wherein:

Y is















15 6. A compound of Claim 3 of the formula:


















wherein the substituents are as follows:



20	Y	A	R ¹
1.		-NH-CH(CH ₂ CH(CH ₃) ₂)(L)	
25	2.	-NH-CH(CH ₂ Ph)(L)	
30	3.	-NH-CH(CH ₂ CH ₂ COOH)(L)	

4.		$-\text{NH}-(\text{CH}_2)_5-$	
5.		$-\text{NH}-\underset{\text{(L)}}{\text{CH}}-\text{Ph}$	$-\text{NH}-(\text{CH}_2)_5-\text{COOH}$
6.		$-\text{NH}-\underset{\text{(L)}}{\text{CH}}-\text{CH}(\text{CH}_3)_2$	
7.		$-\text{NH}-\underset{\text{(L)}}{\text{CH}}-\text{Ph}$	
8.		$-\text{NH}-\underset{\text{(D)}}{\text{CH}}-\text{CH}_3$	$-\text{NH}-(\text{CH}_2)_5-\text{COOH}$
9.		$-\text{NH}-\underset{\text{(D)}}{\text{CH}}-\text{COOH}$	
10.		$-\text{NH}-\underset{\text{(D)}}{\text{CH}}-\text{CH}_3$	

11.		$\begin{array}{c} \text{COOH} \\ \\ \text{---NHCH---} \\ \text{(D)} \end{array}$	
12.			
13.		$\begin{array}{c} \text{CH(CH}_3)_2 \\ \\ \text{---NHCH---} \\ \text{(L)} \end{array}$	$\begin{array}{c} \text{---N---(CH}_2)_2\text{---O---(CH}_2)_2\text{---OH} \\ \text{H} \end{array}$
14.		$\begin{array}{c} \text{(CH}_2)_2\text{---COOH} \\ \\ \text{---NH---CH---} \\ \text{(L)} \end{array}$	$\text{---NH---(CH}_2)_5\text{---COOH}$
15.		$\begin{array}{c} \text{CH}_2\text{C(O)NH}_2 \\ \\ \text{---NHCH---} \\ \text{(L)} \end{array}$	$\begin{array}{c} \text{---N---(CH}_2)_2\text{---O---(CH}_2)_2\text{---OH} \\ \text{H} \end{array}$
16.		$\begin{array}{c} \text{CH}_2\text{CO}_2\text{H} \\ \\ \text{---NHCH---} \\ \text{(D)} \end{array}$	$\begin{array}{c} \text{---N---(CH}_2)_2\text{---O---(CH}_2)_2\text{---OH} \\ \text{H} \end{array}$
17.		$\begin{array}{c} \text{CH}_2\text{CO}_2\text{H} \\ \\ \text{---NHCH---} \\ \text{(D)} \end{array}$	
18.		$\begin{array}{c} \text{CH(CH}_3)_2 \\ \\ \text{---NHCH---} \\ \text{(D)} \end{array}$	$\begin{array}{c} \text{---N---(CH}_2)_2\text{---O---(CH}_2)_2\text{---OH} \\ \text{H} \end{array}$

19.		$\begin{array}{c} \text{CH}_2\text{CH}_2\text{SCH}_3 \\ \\ \text{-NHCH-} \\ \text{(D)} \end{array}$	
5 20.		$\text{-NH(CH}_2)_6\text{-}$	$\text{-N-(CH}_2)_2\text{-O-(CH}_2)_2\text{-OH}$ H
10 21.		$\begin{array}{c} \text{H}_3\text{C-CHCH}_2\text{CH}_3 \\ \\ \text{-NHCH-} \\ \text{(L)} \end{array}$	
15 22.		$\begin{array}{c} (\text{CH}_2)_2\text{CO}_2\text{H} \\ \\ \text{-NHCH-} \\ \text{(D)} \end{array}$	
20 23.		$\begin{array}{c} \text{CH(CH}_3)_2 \\ \\ \text{-NHCH-} \\ \text{(D)} \end{array}$	
24.		$\begin{array}{c} \text{CH}_2\text{CH(CH}_3)_2 \\ \\ \text{-NHCH-} \\ \text{(L)} \end{array}$	
25 25.			
30 26.		$\begin{array}{c} \text{CH}_2\text{CH(CH}_3)_2 \\ \\ \text{-NHCH-} \\ \text{(L)} \end{array}$	$\text{-NH-(CH}_2)_5\text{-COOH}$

	27.			
5	28.			
10	29.			
15	30.			$\text{-NH-(CH}_2\text{)}_5\text{-COOH}$
20	31.		$\text{-NH(CH}_2\text{)}_5\text{-}$	
	32.			$\text{-N-(CH}_2\text{)}_2\text{-O-(CH}_2\text{)}_2\text{-OH}$ H
25	33.			$\text{-N-(CH}_2\text{)}_2\text{-O-(CH}_2\text{)}_2\text{-OH}$ H
30	34.			

35. 	$\begin{array}{c} (\text{CH}_2)_2\text{C}(\text{O})\text{NH}_2 \\ \\ -\text{NHCH}- \\ (\text{L}) \end{array}$	$\begin{array}{c} -\text{N}-(\text{CH}_2)_2-\text{O}-(\text{CH}_2)_2-\text{OH} \\ \text{H} \end{array}$
5 36. 	$\begin{array}{c} (\text{CH}_2)_2\text{CO}_2\text{H} \\ \\ -\text{NHCH}- \\ (\text{L}) \end{array}$	$\begin{array}{c} -\text{N}-(\text{CH}_2)_2-\text{O}-(\text{CH}_2)_2-\text{OH} \\ \text{H} \end{array}$

- 10 7. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 3 and a pharmaceutically acceptable carrier.
- 15 8. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 4 and a pharmaceutically acceptable carrier
- 20 9. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 5 and a pharmaceutically acceptable carrier.
- 10 10. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 6 and a pharmaceutically acceptable carrier.
- 25 11. A method of inhibiting serine proteases in a mammal which comprises administering to said mammal an effective amount of a compound of Claim 5.
12. A method of inhibiting carbonic anhydrase isozymes in a mammal which comprises administering to said mammal an effective amount of a compound of Claim 6.
- 30 13. A method of identifying a ligand having a desired characteristic which comprises synthesizing a combinatorial library of Claim 1 and testing the compounds in said library in an assay which identifies compounds having the desired characteristic.

14. A method of Claim 13 further comprising determining the structure of any ligand so identified.
15. A method of identifying a ligand having a desired characteristic which comprises synthesizing a combinatorial library of
5 Claim 1, detaching the ligands from the solid supports in said library, and testing said ligands in an assay which identifies compounds having the desired characteristic.
16. A method of Claim 15 further comprising determining the structure of any ligand so identified.
- 10 17. A process for preparing t-butyl 4-(hydroxymethyl)-3-nitrobenzoate from t-butyl 4-(acetoxymethyl)-3-nitrobenzoate which comprises reacting t-butyl 4-(acetoxymethyl)-3-nitrobenzoate with hydrazine or hydrazine hydrates in a polar solvent and an aprotic polar solvent at 0-50 °C.
- 15 18. The use of divinylbenzene-cross-linked, polyethyleneglycol-grafted polystyrene beads as the solid supports for constructing non-oligomeric combinatorial libraries.
19. A method of Claim 18 wherein the ligand is detached from said solid supports by photolysis.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/03223

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : Please See Extra Sheet.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, A, 5,281,585 (DUGGAN ET AL) 25 JANUARY 1994, COLUMN 3 LINE 1 TO COLUMN 9 LINE 17..	1-12
Y,P	WO, A, 94/08051 (STILL ET AL) 14 APRIL 1994, PAGE 81.	1-12
Y	WO, A, 93/20242 (LERNER ET AL) 14 OCTOBER 1993, PAGE 4 LINES 15 +.	1-12
Y	WO, A, 93/06121 (DOWER ET AL) 01 APRIL 1993, PAGE 16 LINES 4 +.	1-12

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search 01 JUNE 1995	Date of mailing of the international search report 30 JUN 1995
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer RAYMOND COVINGTON Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US95/03223

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

X

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐

The additional search fees were accompanied by the applicant's protest.

☐

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US95/03223

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

A61K 31/095, 38/09, 39/44; C07C 69/06; C07C 211/00, 211/06, 233/19, 233/22, 317/14, 323/22, 323/33, ; C07D 207/00, 233/54, 285/10, 307/64, 315/00, 333/34, 333/36; C08F 6/00, 8/00, 8/40, 112/08; C09K 3/00; C12N 1/00; C12P 19/34; C12Q 1/00; G01N 33/53

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

252/182.11; 435/7.92, 91, 960, 973; 514/913; 525/59, 61; 526/341, 347.2; 528/486, 487, 491; 546/216, 219, 221, 226, 227, 229, 233, 235, 236, 237, 238; 548/135, 311.1, 401, 530, 539, 540; 549/3, 64, 201, 479; 560/106; 562/430; 564/154, 162, 305

B. FIELDS SEARCHED

Minimum documentation searched

Classification System: U.S.

252/182.11; 435/7.92, 91, 960, 973; 514/913; 525/59, 61; 526/341, 347.2; 528/486, 487, 491; 546/216, 219, 221, 226, 227, 229, 233, 235, 236, 237, 238; 548/135, 311.1, 401, 530, 539, 540; 549/3, 64, 201, 479; 560/106; 562/430; 564/154, 162, 305

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

I. Claims 1-2, 13-16 drawn to the compound of formula I and a method of using.

II. Claims 3-10 drawn to a composition of the compound of formula II.

III. Claims 11, 12 drawn to a method of using the compound of Group II.

IV. Claim 17, drawn to a process for making nitrobenzoate.

V. Claims 18-19 drawn to a method of using polystyrene beads as solid supports.

The inventions listed as Groups I- V do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

There is no technical relationship between the above listed invention groups involving a corresponding special technical feature. Multiple products, processes and uses are claimed and groups of inventions are not so linked as to form a single general inventive concept under 37CFR 1.475.